Quest Diagnostics has made multiple recent strides in the biotech market, marked by launches of FDA-cleared diagnostics tests, strong earnings, acquisitions, and partnerships. They have released an Alzheimer's diagnostic blood test that boasts 97% accuracy, much to the interest of the medical community. With the company's stocks seeing significant growth, up by 27.3% year-on-year, the firm is an appealing pick for portfolios. In an exciting development, Quest is collaborating with
Google Cloud for data streamlining and enhancing customer experiences by leveraging
Generative AI. Several earnings reports have been published, with Q1 2025 results showing robust revenue growth and overall positive performance. Moreover, the acquisition of the Outreach Lab Services of University Hospitals marked an aggressive upward movement for the company. An unexpected collaboration with MD Anderson is expected to result in an innovative Multi-cancer Stratification Blood Test. Finally, the announcement of a partnership with Google Cloud brings a promising AI perspective to diagnostics, proving Quest's innovative stance.
Quest Diagnostics DGX News Analytics from Wed, 21 Aug 2024 07:00:00 GMT to Fri, 11 Jul 2025 23:25:52 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor -2
